Related Experiment Videos
Expression and purification of recombinant rabbit factor VII
S M Ruiz1, S Sridhara, M A Blajchman
1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Researchers successfully created and purified a rabbit version of a blood-clotting protein called factor VII. This protein was produced in human kidney cells and tested to ensure it functions correctly in blood samples. This tool will help scientists study how blood clots form in animal models.
Area of Science:
- Molecular biology research within recombinant factor VII production
- Hematology and coagulation studies
Background:
No prior work had resolved the precise sequence of rabbit factor VII to support detailed coagulation research. That uncertainty drove the need for accurate genetic characterization of this specific clotting protein. Prior research has shown that the extrinsic pathway plays a major role in hemostasis. This gap motivated the isolation of full-length genetic material from phage libraries. Scientists previously relied on incomplete or potentially inaccurate amino acid predictions for this species. Establishing a reliable source of the protein remains a hurdle for experimental thrombosis models. This study addresses the lack of verified sequence data for rabbit-derived coagulation factors. Investigators required a standardized method to produce and isolate this protein for functional testing.
Purpose Of The Study:
The aim of this study was to produce and purify recombinant rabbit factor VII to support coagulation research. Scientists sought to resolve discrepancies in the previously reported amino acid sequence of this clotting factor. The researchers intended to establish a stable cell line capable of secreting the protein for experimental use. This work addresses the need for a reliable supply of the protein to study the extrinsic pathway. The team aimed to verify the biological activity of the purified product in various plasma environments. They wanted to ensure the recombinant form matched the functional characteristics of the native protein. This effort provides a necessary tool for investigating hemostasis and thrombosis in animal models. The study focuses on creating a standardized preparation for future in vivo investigations of coagulopathies.
Main Methods:
The review approach involved isolating genetic material from plaque-purified phage libraries using polymerase chain reaction. Investigators performed repeated sequencing to verify the amino acid composition of the target molecule. The team established a permanent cell line by transfecting human embryonic kidney cells with the verified genetic construct. They collected the secreted protein from the tissue culture media for subsequent isolation. The purification strategy combined chemical precipitation with multiple chromatography steps to ensure high yields. Researchers utilized affinity-based capture with specific polyclonal antibodies to achieve high purity. They assessed the molecular identity of the final product using gel electrophoresis and immunoblotting techniques. The study design focused on achieving a homogeneous protein preparation for functional validation.
Main Results:
Key Findings From the Literature indicate the mature protein consists of 405 amino acids. The researchers identified four distinct changes compared to previously published sequences for this rabbit-derived factor. The purification process yielded a homogeneous product that demonstrated full biological activity. This activity was confirmed using prothrombin time assays in factor-depleted plasma. The protein successfully initiated clotting in both human and rabbit plasma samples. The team utilized both human and rabbit thromboplastin to verify the functional consistency of the recombinant molecule. Western blot analysis confirmed the authenticity of the purified protein against known standards. The established cell line provides a reliable source for ongoing production of this clotting factor.
Conclusions:
Synthesis and Implications suggest this recombinant protein provides a valuable resource for future animal model investigations. The authors propose that the established cell line allows for consistent production of the clotting factor. This study confirms that the purified protein retains full biological activity across different plasma types. Researchers indicate that the corrected amino acid sequence improves the accuracy of future structural studies. The findings demonstrate that human kidney cells can effectively process and secrete this rabbit-derived molecule. The authors state that the purified product functions correctly in both human and rabbit-based clotting assays. This work provides a foundation for exploring experimental coagulopathies in vivo. The evidence supports the utility of this recombinant tool for standardized hemostasis research.
Frequently Asked Questions
The researchers propose that the protein functions by initiating the extrinsic coagulation pathway. They confirmed this activity using prothrombin time assays, which measure the time required for plasma to clot when exposed to thromboplastin. This process works in both human and rabbit-derived samples.
The team utilized a multi-step purification protocol involving barium citrate precipitation, DEAE-sepharose FF chromatography, and benzamidine agarose. They finalized the isolation process using affinity chromatography with sheep-derived polyclonal antibodies specific to the rabbit factor.
The authors state that human embryonic kidney 293 cells are necessary for the stable expression of the protein. These cells provide the required cellular machinery to process and secrete the rabbit-derived factor VII into the surrounding culture media.
The researchers used DNA sequencing to verify the genetic code of the protein. This data confirmed four specific changes in the previously reported amino acid sequence, resulting in a mature protein length of 405 amino acids.
The team confirmed the purity and authenticity of the protein through polyacrylamide gel electrophoresis and Western blot analysis. These methods allowed the investigators to verify the molecular weight and identity of the final purified product.
The authors suggest that this recombinant factor will facilitate future in vivo investigations of experimental coagulopathies. They propose that having a reliable supply of the protein will improve the study of hemostasis and thrombosis in animal models.